#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Tod M. Woolf

Serial No.: 10/071,512

Filed: February 8, 2002

For *Methods of Light Activated Release of Ligands from Endosomes*

Attorney Docket No.: SRI-014

Group Art Unit: 1615

Examiner:

U.S. Patent and Trademark Office
Box Sequence
Post Office Box 2327
Arlington, VA 22202

TRANSMITTAL LETTER FOR DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing filed for the above-identified patent application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The information recorded in computer readable form is identical to the written Sequence Listing appearing on pages 1-3 submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of §§ 1.824 and 1.825.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on:

October 1, 2002
Date

Megan E. Williams, Esq. Reg. No. 43,270

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicant

SEQUENCE LISTING

<110> Woolf, Tod M.

<120> METHODS OF LIGHT ACTIVATED RELEASE OF LIGANDS FROM ENDOSOMES

<130> SRI-014

<140> US 10/071512
<141> 2002-02-08

<150> US 60/267272
<151> 2001-02-08

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct

<400> 1
His Ile Trp Leu Ile Tyr Leu Trp Ile Val
1 5 10

<210> 2
<211> 16
<212> PRT
<213> Drosophila melanogaster

<400> 2
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 3
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct

<400> 3
Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
1 5 10 15
Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
20 25

<210> 4
<211> 25
<212> PRT
<213> Human immunodeficiency virus

<220>
<221> BLOCKED
<222> 1
<223> Acm protecting group

<400> 4
Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg
 1   5   10   15
Arg Gln Arg Arg Arg Pro Pro Gln Cys
            20   25

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> variant of Seq Id No. 4

<400> 5
Cys Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln Cys
 1   5   10   15

<210> 6
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> variant of Seq Id No. 4

<400> 6
Cys Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Pro
 1   5   10   15
Pro Gln Cys

<210> 7
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> variant of Seq Id No. 4

<400> 7
Gly Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys
 1   5   10   15
Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr His Gln Val

20 25 30

Ser Leu Ser Lys Gln

35